ArticleScientific reports2026
Investigating bioactive potential of the Serratia sp. CS01 and its pigment for anti-inflammatory, antioxidant and antibacterial action.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial proteases and pigments contain biomolecular properties with considerable therapeutic and industrial applications. In the present investigation, a bacterial isolate named CS01 was taxonomically identified as Serratia sp., utilizing 16S rDNA sequencing. HPLC, MALDI-TOF analysis and SDS-PAGE (~ 60 kDa band) shows the presence of an anti-inflammatory protease. In addition, a red pigment was extracted from the isolate and identified as prodigiosin-like pigment, confirmed through UV-Vis spectrophotometry, FTIR, HPLC and HRMS analysis. The cell free supernatant showed Human red blood cell membrane stabilization of 79.3 ± 0.007%, while the pigment extract showed high stability of 95.33 ± 0.004%. The heat-induced haemolysis revealed 87.18 ± 0.003% of membrane protection for the cell free supernatant 95.57 ± 0.005% for pigment sample, showing comparable efficacy to that of diclofenac (94.37 ± 0.003%). The crude and pigment sample from CS01 also showed the ability to inhibit egg albumin denaturation with a range of 80.31 ± 0.01% and 85.6 ± 0.005%. In addition, Serratia sp. CS01 exhibited 55.93 ± 0.008% of antioxidant activity and its pigment showed 91.26 ± 0.28% at 1000 µg/mL. Antibacterial studies revealed the ability of the strain to inhibit the growth of Escherichia coli, Bacillus cereus, and Staphylococcus aureus. The MIC results for the pigment sample exhibited higher antibacterial efficacy in comparison to the crude extract, attaining inhibition rates nearing 90% within a concentration spectrum (10-150 µg/mL). Collectively, these results summarize that Serratia sp. CS01 simultaneously produces both anti-inflammatory protease and prodigiosin-like pigment having anti-inflammatory, antioxidant, and antibacterial properties. This highlights Serratia sp. CS01 as a promising microbial source of multifunctional biomolecules with prospective therapeutic and industrial applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.